Chicago River Bridge

Early stage clinical trials can often turn out to be a bridge to future success or an unexpected dunk in the water, depending on how the outcomes go.

The path to success in Developmental Therapeutics is often paved with many unexpected trials and tribulations.

The important factor though is not whether or not companies experience them – because they will – but how well they handle the issues which present along the way.

In our latest report from ASCO23 we take a look at three phase 1 trials and one phase 2 study to explore the opportunities and challenges involved for four very different companies…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by